<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the effectiveness of prophylactic FOLFOX after curative resection of synchronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Clinicopathological information including postoperative chemotherapy, such as a therapeutic regimen, relapse-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>), site of recurrence, etc., was retrospectively analyzed in 116 CRC patients with synchronous distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, and 63 patients with metachronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> who had received surgery in our hospital between 2000 and 2009 </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-three patients (84%) out of 63 without adjuvant chemotherapy, and 38 (83%) out of 46 patients that received oral or intravenous <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) (alone or with leucovorin (LV)or isovorin) developed <z:e sem="disease" ids="C0521158" disease_type="Neoplastic Process" abbrv="">recurrent tumor</z:e>(s) afterwards </plain></SENT>
<SENT sid="3" pm="."><plain>The median RFSs were 119 and 281 days, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>By contrast, a single patient among 6 who underwent FOLFOX (up to 12 therapeutic courses) showed recurrence 476 days after surgery </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> of the FOLFOX was significantly higher than that of the 5-FU (+LV) or surgery alone (p=0 </plain></SENT>
<SENT sid="6" pm="."><plain>03, p=0 </plain></SENT>
<SENT sid="7" pm="."><plain>007, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, the FOLFOX regimen is more beneficial for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with synchronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> as adjuvant chemotherapy than 5-FU (+LV) or other followup strategies </plain></SENT>
</text></document>